ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually providing an update on the usage of its “at-the market” equity offering program.

As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Wainwright & Co., LLC (collectively, the “Agents”), to implement a “at the market” equity offering system under which Acasti may well issue and promote from time to time its common shares having an aggregate offering price of up to $75 million in the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions found on January twenty seven, 2021, Acasti issued an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 zillion. The ATM Shares ended up being marketed at prevailing market rates averaging US$1.0747 a share. No securities had been sold through the facilities of the TSXV or perhaps, to the knowledge of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with the services of theirs. As a result of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and outstanding as of March five, 2021.

The additional capital raised has strengthened Acasti’s balance sheet and often will provide the Company with extra flexibility in its continuous review process to explore as well as evaluate strategic options.

About Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically concentrated on the research, commercialization and development of prescribed drugs making use of OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of efficacy and safety in lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for patients with serious HTG.

Forward Looking Statements – ACST Stock

Statements of that press release that aren’t statements of historical or current truth constitute “forward-looking information” to the meaning of Canadian securities laws as well as “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking assertions include known and unknown risks, uncertainties, along with other unknown components that might cause the particular outcomes of Acasti to be materially different from historical success and even as a result of any future outcomes expressed or implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be forward-looking and uncertain. People are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the day of this press release. Forward-looking claims in this press release include, but are not confined to, statements or info concerning Acasti’s strategy, succeeding operations and its review of strategic options.

The forward looking claims found in this specific press release are expressly qualified in the entirety of theirs by this alerting declaration, the “Special Note Regarding Forward-Looking Statements” section in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com as well as on the investor aisle of Acasti’s website at www.acastipharma.com. Many forward looking assertions in this press release are manufactured as of the day of this press release.

ACST Stock – Acasti does not undertake to update some such forward-looking statements whether as a result of info that is brand new , future events or perhaps otherwise, except as needed by law. The forward-looking claims contained herein are also subject typically to assumptions and risks and uncertainties that are described from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, like Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q under the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually giving an update on the use